265 filings
Page 3 of 14
8-K
ez38xkqd0pfu9e vl5
11 Feb 19
Immunomedics Announces Oral Presentation at the 2019 Genitourinary Cancers Symposium
5:25pm
8-K
ikgc1 h5107y1gk8io
7 Feb 19
Other Events
4:30pm
8-K
0byq9zcou7kap7r
18 Jan 19
Immunomedics Receives Complete Response Letter from Fda for Sacituzumab Govitecan Biologics License Application
12:00am
8-K
i570o7dbc
16 Jan 19
Other Events
12:00am
8-K
o64jf2 ys7p5jofu2
28 Dec 18
Entry into a Material Definitive Agreement
8:58am
8-K
q8dd6 ygsj
26 Dec 18
Immunomedics and Johnson Matthey Announce Strategic Manufacturing Partnership
8:30am
8-K
7jdjn zqz0
17 Dec 18
Amendments to Articles of Incorporation or Bylaws
5:01pm
8-K
72bqip
7 Nov 18
Immunomedics Announces First Quarter Fiscal 2019 Results and Provides Corporate Update
4:06pm
8-K
sfcao vga1haefne2
3 Oct 18
Entry into a Material Definitive Agreement
8:15am
8-K
yi7yass1u0ehx ug
28 Sep 18
Departure of Directors or Certain Officers
4:30pm
8-K
74pmdd60o096tgh 81a
12 Sep 18
Immunomedics and Samsung Biologics Announce Strategic Manufacturing Partnership
12:00am
8-K
peefapwxi
23 Aug 18
Departure of Directors or Certain Officers
12:00am
8-K
0se epul540qvw1irq
23 Aug 18
Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update
12:00am
8-K
6r54z
18 Jul 18
Other Events
8:15am
8-K
3yxursgwxd trzqphssw
12 Jul 18
Entry into a Material Definitive Agreement
4:30pm
8-K
cxq4c96 nw3g8mz
22 Jun 18
Other Events
4:33pm
8-K
dhgu47lq rda9
15 Jun 18
Immunomedics Announces Proposed Public Offering of Common Stock
4:00pm
8-K
5vg0r1 us
4 Jun 18
Immunomedics Announces Pivotal Study of Sacituzumab Govitecan In Patients with Locally Advanced or Metastatic Urothelial Cancer
12:00am
8-K
qfcbtoit r8omm
4 Jun 18
Immunomedics Provides Business Update at the Asco 2018 Investor Event
12:00am
8-K
kruk5510h4tu pbc0pye
9 May 18
Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update
4:01pm